• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risankizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the Phase 3 INSPIRE and COMMAND Studies.

出版信息

Gastroenterol Hepatol (N Y). 2024 Jul;20(7 Suppl 6):11-13.

PMID:39193121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11345978/
Abstract
摘要

相似文献

1
Risankizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the Phase 3 INSPIRE and COMMAND Studies.在3期INSPIRE和COMMAND研究中，使用瑞莎珠单抗治疗中度至重度活动性溃疡性结肠炎患者。
Gastroenterol Hepatol (N Y). 2024 Jul;20(7 Suppl 6):11-13.
2
Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study.中度至重度活动性溃疡性结肠炎患者的瑞莎珠单抗诱导治疗：3期随机INSPIRE研究中的疗效与安全性
Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):9-10.
3
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.依特利珠单抗与英夫利昔单抗治疗中重度活动性溃疡性结肠炎（GARDENIA）的随机、双盲、双模拟、3 期研究。
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17.
4
Ozanimod: A Review in Ulcerative Colitis.奥扎莫德：溃疡性结肠炎的研究进展。
Drugs. 2022 Aug;82(12):1303-1313. doi: 10.1007/s40265-022-01762-8. Epub 2022 Aug 22.
5
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.以艾托珠单抗对比阿达木单抗或安慰剂作为中度至重度活动性溃疡性结肠炎诱导治疗（HIBISCUS）：两项3期随机对照试验
Lancet Gastroenterol Hepatol. 2022 Jan;7(1):17-27. doi: 10.1016/S2468-1253(21)00338-1. Epub 2021 Nov 17.
6
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.乌帕替尼作为中度至重度活动溃疡性结肠炎的诱导和维持治疗：三项 3 期、多中心、双盲、随机临床试验的结果。
Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26.
7
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.依特利珠单抗用于中重度活动性溃疡性结肠炎患者的维持治疗（LAUREL）：一项随机、安慰剂对照、双盲、3 期研究。
Lancet Gastroenterol Hepatol. 2022 Jan;7(1):28-37. doi: 10.1016/S2468-1253(21)00295-8. Epub 2021 Nov 17.
8
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.依特立珠单抗诱导和维持治疗中重度溃疡性结肠炎的疗效和安全性：一项随机、双盲、安慰剂对照的 3 期临床研究
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17.
9
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.利斯利珠单抗作为中重度活动期克罗恩病的维持治疗：来自多中心、随机、双盲、安慰剂对照、撤药期 3 期 FORTIFY 维持试验的结果。
Lancet. 2022 May 28;399(10340):2031-2046. doi: 10.1016/S0140-6736(22)00466-4.
10
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.对接受8周诱导治疗有反应的中度至重度活动性溃疡性结肠炎患者进行乌帕替尼维持治疗的疗效和安全性（U-ACHIEVE维持治疗）：随机、安慰剂对照、双盲3期维持研究的总体结果
Lancet Gastroenterol Hepatol. 2023 Nov;8(11):976-989. doi: 10.1016/S2468-1253(23)00208-X. Epub 2023 Sep 9.

引用本文的文献

1
Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials.无论基线改良梅奥评分如何，mirikizumab治疗中度至重度活动性溃疡性结肠炎的疗效和安全性：3期LUCENT试验结果
Crohns Colitis 360. 2025 Jan 8;7(2):otaf002. doi: 10.1093/crocol/otaf002. eCollection 2025 Apr.

本文引用的文献

1
Analysis of Upadacitinib in IBD: Evaluating Safety and Efficacy Across Phase 3 Trials in Patients With Crohn's Disease or Ulcerative Colitis.乌帕替尼在炎症性肠病中的分析：评估克罗恩病或溃疡性结肠炎患者3期试验中的安全性和疗效。
Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 8):9-10.
2
Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody.白细胞介素23（IL23）通路的选择性靶向：一种新型高亲和力人源化抗IL23A抗体的产生与特性分析
MAbs. 2015;7(4):778-91. doi: 10.1080/19420862.2015.1032491. Epub 2015 Apr 23.